Market Place
Sourcing Support
CatalYm Secures $150M For Visugromab Phase 2b Development Program
16 Jul 2024 //
BUSINESSWIRE
CatalYm cashes in on early-stage cancer data with $150M series D
16 Jul 2024 //
FIERCE BIOTECH
CatalYm`s Visugromab/Nivolumab Combo Shows Responses In Late-Line Cancers
02 Jun 2024 //
BUSINESSWIRE
Catalym Gdf-15 Visugromab Positive: Ph2a Nsclc Urothelial Hcc Asco 2024
23 May 2024 //
BUSINESSWIRE
CatalYm Appoints Drug Development Leader Roy Baynes to its Board of Directors
08 Jan 2024 //
BUSINESSWIRE
CatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC
06 Dec 2023 //
BUSINESSWIRE
German biotech’s efforts to revive obesity target yield positive PhIIa results
06 Dec 2023 //
ENDPTS
CatalYm Presents Data at SITC 2023 Annual Meeting
31 Oct 2023 //
BUSINESSWIRE
CatalYm commences Dosing in a Phase 2 Study with Visugromab
26 Oct 2023 //
BUSINESSWIRE
CatalYm Presents Data at ESMO 2023 Expanding GDF-15’s Role
15 Oct 2023 //
BUSINESSWIRE
CatalYm Publishes Data in Nature Communications Describing GDF-15
20 Jul 2023 //
BUSINESSWIRE
CatalYm Announces Initial Data from Ongoing Phase 2a Trial Evaluating GDF-15
05 Jun 2023 //
BUSINESSWIRE
CatalYm to Present Phase 2a Data on Visugromab
25 May 2023 //
BUSINESSWIRE
CatalYm Closes EUR 50 Million Series C Financing
22 Nov 2022 //
BUSINESSWIRE
German biotech CatalYm raises $50M to flip weight loss target for cancer
22 Nov 2022 //
ENDPTS
CatalYm Receives FDA IND Clearance to Expand Development of Visugromab
26 Sep 2022 //
BUSINESSWIRE
CatalYm Demonstrates Efficacy in Human PI Trial for Visugromab & Nivolumab
10 Sep 2022 //
BUSINESSWIRE
CatalYm to Present PI Safety & Efficacy Data on GDF-15 Visugromab (CTL-002)
04 Sep 2022 //
BUSINESSWIRE
CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002
01 Mar 2022 //
BUSINESSWIRE
CatalYm Presents Updated Data from GDF-15 First-in-Human Clinical Trial
11 Oct 2021 //
BUSINESSWIRE
CatalYm to Present Data of First-in-Human Trial of CTL-002 at the ASCO Meeting
20 May 2021 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.